Amphastar Announces FDA Approval for Ipratropium Bromide HFA

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Ipratropium Bromide HFA Inhalation Aerosol 17mcg/actuation. The FDA determined that Amphastar's Ipratropium Bromide HFA Inhalation Aerosol is bioequivalent and therapeutically equivalent to Boehringer Ingelheim's Atrovent® HFA Inhalation Aerosol.

Accesswire • 13 hours ago

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2025 ended December 31, 2025, after the market closes on Thursday, February 26, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Accesswire • Feb 20, 2026

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 15, 2026

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA / ACCESS Newswire / January 12, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that it has entered into an exclusive license agreement (the "Agreement") with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ("Hanxin") for the development, and commercialization of a fully synthetic and highly purified human adrenocorticotropic hormone (ACTH) analogs (also termed corticotropin), now designated AMP-110, in the United States and Canada.

Accesswire • Jan 12, 2026

Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / January 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14th, 2026, at 2:15 pm PT.

Accesswire • Jan 7, 2026

Amphastar Director Sells 16,679 Shares for $441,800

Floyd Petersen exercised and sold 16,679 shares of Amphastar in November, pocketing more than $441,000. He still retains about $2 million worth of shares.

The Motley Fool • Dec 23, 2025

Amphastar Announces FDA Approval for Teriparatide Injection

RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for teriparatide injection, USP 560 mcg/2.24mL (250 mcg/mL) single-patient-use prefilled pen. The FDA determined that Amphastar's teriparatide is bioequivalent and therapeutically equivalent to Eli Lilly's FORTEO®.

Accesswire • Dec 15, 2025

Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / November 24, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be participating in an Analyst-Moderated fireside chat at the 37th Annual Piper Sandler Healthcare Conference on Wednesday, December 3rd, 2025, at 2:00 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

Accesswire • Nov 24, 2025

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / November 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Wednesday, November 19th, 2025, at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

Accesswire • Nov 12, 2025

Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2025 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. ( AMPH ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Communication William Peters - CFO, Executive VP of Finance, Treasurer & Director Tony Marrs - Executive VP of Regulatory Affairs & Clinical Operations Conference Call Participants Serge Belanger - Needham & Company, LLC, Research Division Pavan Patel - BofA Securities, Research Division Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division David Amsellem - Piper Sandler & Co., Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Presentation Operator Greetings, and welcome to the Amphastar Pharmaceuticals, Inc. Third Quarter Earnings Call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not historical facts, including, but not limited to, management's outlook or predictions for the future periods are forward-looking statements.

Seeking Alpha • Nov 8, 2025